Our findings indicate that the combination of src inhibition and gemcitabine may be a potential therapeutic strategy to sensitize gemcitabine-resistant breast cancer cells to gemcitabine through AKT/c-Jun pathway. The gene discussed is JUN; the disease is breast cancer.